Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CETP | P11597 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GMNN | O75496 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | THPO | P40225 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | UBE2N | P61088 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.42 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21428085 | 0.78 | SPHK1 (0.55) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL21636787 | 0.78 | SPHK1 (0.55) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL15057401 | 0.78 | SPHK1 (0.55) | SPHK1CYP2D6LMNACETPMAPT | |
| Hydrochloric Acid SCHEMBL7612591 | 0.77 | SPHK1 (0.53) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL1630183 | 0.76 | SPHK1 (0.52) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL8609400 | 0.73 | MEN1 (0.51) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL22986826 | 0.71 | MEN1 (0.49) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL118392 | 0.71 | LMNA (0.65) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL15013420 | 0.71 | LMNA (0.65) | SPHK1CYP2D6LMNACETPMAPT | |
| SCHEMBL25243382 | 0.71 | LMNA (0.65) | SPHK1CYP2D6LMNACETPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228667-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | Brightseed, Inc. (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | claimed |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2026-05-19 | — | — | US | disclosed |
| EP-4465976-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | Brightseed, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-20240374546-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | BRIGHTSEED INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-11974969-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2024-05-07 | — | — | US | disclosed |
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4228667-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | Brightseed, Inc. (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2023141427-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | BRIGHTSEED, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20220362182-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2022-11-17 | — | — | US | disclosed |
| WO-2022081567-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | BRIGHTSEED, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240099993-A1 | ARTIFICIALLY SYNTHESIZED SPHINGOSINE DERIVATIVE LIPOID MONOMER AND USE OF SAME FOR DELIVERING NUCLEIC ACID | SPHK2, SPHK1, S1PR2 | SPHK1 2/4885CYP2D6 4037/4885LMNA 220/4885 |
| US-20220362182-A1 | METHODS FOR REVERSING HEPATIC STEATOSIS | FABP1, CPT1A, LIPC | SPHK1 687/4885CYP2D6 3943/4885LMNA 537/4885 |
| US-12629421-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | S1PR2, S1PR3, S1PR1 | SPHK1 8/4885CYP2D6 4264/4885LMNA 77/4885 |
| US-20240374546-A1 | USES AND METHODS FOR PROMOTING INCREASED MITOCHONDRIAL MASS AND FUNCTION | TFAM, NDUFAB1, TUFM | SPHK1 3273/4885CYP2D6 2209/4885LMNA 892/4885 |
| US-11974969-B2 | Artificially synthesized sphingosine derivative lipoid monomer and use of same for delivering nucleic acid | SPHK2, SPHK1, S1PR2 | SPHK1 2/4885CYP2D6 4037/4885LMNA 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.